Table 2.

Most Common (≥5% of All Patients) Grades 3–4 TEAEs

AE	CC-486 200 mg QD for 7 Days (n = 3)	CC-486 300 mg QD for 7 Days (n = 4)	CC-486 150 mg QD for 14 Days (n = 4)	CC-486 200 mg QD for 14 Days (n = 19)	Total (N = 30)
Patients with ≥1 grade 3–4 TEAE	2 (67)	3 (75)	3 (75)	14 (74)	22 (73)
Hematologic
Lymphopenia	0	0	3 (75)	3 (16)	6 (20)
Neutropenia	0	0	1 (25)	4 (21)	5 (17)
Anemia	0	0	1 (25)	3 (16)	4 (13)
Thrombocytopenia	1 (33)	0	0	2 (11)	3 (10)
gastrointestinal
Diarrhea	1 (33)	0	2 (50)	3 (16)	6 (20)
Vomiting	1 (33)	1 (25)	1 (25)	2 (11)	5 (17)
Nausea	1 (33)	0	0	3 (16)	4 (13)
GI GVHD*	0	0	0	3 (16)	3 (10)
Abdominal pain	0	0	0	2 (11)	2 (7)
Other
Device-related infection	0	1 (25)	1 (25)	0	2 (7)
Dehydration	0	0	1 (25)	1 (5)	2 (7)
Pneumonia	0	0	1 (25)	1 (5)	2 (7)

Values are n (%). GI indicates gastrointestinal.

^*Acute or chronic.